A Study of Thyroid Function Abnormalities in Patients with Chronic Kidney Disease by Rajesh, S
A Dissertation on 
A STUDY OF THYROID FUNCTION ABNORMALITIES IN PATIENTS 
WITH CHRONIC KIDNEY DISEASE 
 Dissertation Submitted to 
THE TAMILNADU DR. MGR MEDICAL UNIVERSITY 
CHENNAI – 600 032 
With Partial Fulfillment of the Regulations  
For the Award of the Degree of 
 
 
M.D. GENERAL MEDICINE 
BRANCH – I 
 
COIMBATORE MEDICAL COLLEGE, 
COIMBATORE 
 
APRIL 2016 
  
CERTIFICATE 
This is to certify that the dissertation entitled “A STUDY OF THYROID 
FUNCTION ABNORMALITIES IN PATIENTS WITH CHRONIC KIDNEY 
DISEASE” is a bonafide research work done by Dr. RAJESH.S, Post Graduate 
student in General Medicine, under my direct guidance and supervision. This is being 
submitted to the The Tamil Nadu Dr. M.G.R. Medical University, Chennai, in partial 
fulfillment of the regulations for the award of M.D. Degree in General Medicine 
examination to be held in April 2016. I have great pleasure in forwarding the same to 
The Tamil Nadu Dr. M.G.R. Medical University, Chennai, Tamilnadu, India. 
 
 
 
 
  
Dr. M.RAVEENDRAN, M.D.,    Dr. KUMAR NATARAJAN, M.D., 
Professor and Guide      Professor, 
Chief Medical Unit – V    Head of the Department  
Department of Medicine,    Department of Medicine 
Coimbatore Medical College       Coimbatore Medical College        
                                                                                                
                                                   
 
 
 
 
 
Dr. A. EDWIN JOE M.D., B.L., 
The Dean 
Coimbatore Medical College 
Coimbatore 

  
  
  
 
 
 
 
 
 
 
 
 
Declaration  
THE TAMILNADU DR.M.G.R MEDICAL UNIVERSITY 
CHENNAI 
DECLARATION BY THE CANDIDATE 
 
             I, Dr. RAJESH.S hereby declare that this dissertation entitled “A STUDY 
OF THYROID FUNCTION ABNORMALITIES IN PATIENTS WITH 
CHRONIC KIDNEY DISEASE” is a bonafide and genuine research work 
carried out by me under the guidance of Prof. Dr.M.RAVEENDRAN, M.D., 
Department of Medicine, Coimbatore Medical College, Coimbatore, in partial 
fulfillment of the regulations for the award of M.D. Degree in General Medicine to 
be held in April 2016. 
 
             This dissertation has not been submitted by me on any previous occasion to 
any university for the award of any degree. 
 
 
Date: 
Place: Coimbatore                                                                Dr.RAJESH.S 
 
                                                                                       Post Graduate student 
                                                                                      Department of Medicine 
                                                                                   CoimbatoreMedicalCollege 
                                                                                                 Coimbatore  
  
  
 
 
 
 
 
 
 
 
 
Acknowledgement 
ACKNOWLEDGEMENT 
 
 
I wish to express my sincere thanks to our respected Dean                                
Dr. A.EDWIN JOE M.D.,B.L., for having allowed me to conduct this study in our 
hospital.  
I express my heartfelt thanks and deep gratitude to the Head of the Department 
of Medicine, Prof. Dr. KUMAR NATARAJAN M.D., for his generous help and 
guidance in the course of the study.  
I owe a great debt of gratitude to our respected Professor and unit chief          
Prof. Dr. M.RAVEENDRAN M.D., without whose help and advice this work would 
not have been possible. 
I sincerely thank all Professors and Asst. Professor                                          
Dr. S. AVUDAIAPPAN M.D., Dr. A. NILAVAN M.D., for their guidance and kind 
help. 
I am extremely grateful to Dr. PRABAHARAN M.D., D.M., 
(NEPHROLOGY), Dr. SUNDARI M.D., (RADIODIAGNOSIS).,                    
Dr. MANIMEGALAI.N M.D., (BIOCHEMISTRY)., for his valuable help 
and cooperation for allowing me to use institutional facilities. 
My sincere thank to all my friends and post-graduate colleagues for their whole 
hearted support and companionship during my studies. 
I thank all my PATIENTS, who formed the backbone of this study, without 
them this study would not have been possible.  
 CONTENTS  
 
S. NO. CONTENT PAGE NO. 
1 INTRODUCTION 1 
2 AIMS AND OBJECTIVES 4 
3 REVIEW OF LITERATURE 5 
4 MATERIALS AND METHODS 47 
5 RESULTS AND ANALYSIS 51 
6 DISCUSSION 74 
7 CONCLUSION  81 
8 SUMMARY 82 
9 BIBILIOGRAPHY  
10 
ANNEXURES 
A) PROFORMA 
B) MASTER CHART 
C) CONSENT FORM 
 
 
LIST OF TABLES 
 
SI. 
NO TITLE 
PAGE 
NO 
1.  
DIFFERENCE BETWEEN PRIMARY AND 
SECONDARY HYPOTHYROIDISM 10 
2.  
CONDITIONS CAUSING NON-THYROIDAL 
ILLNESS 14 
3.  CLASSIFICATION OF CKD 21 
4.  
EFFECT OF THYROID DYSFUNCTION ON THE 
KIDNEY  36 
5.  AGE WISE DISTRIBUTION OF CASES 51 
6.  SEX WISE DISTRIBUTION OF CASES  52 
7.  AGE/SEX DISTRIBUTION OF CASES 53 
8.  DURATION OF CKD SYMPTOMS 54 
9.  
DISTRIBUTION OF CREATININE CLEARANCE 
IN CKD PATIENTS 55 
10. 
DISTRIBUTION OF BLOOD UREA IN CKD 
PATIENTS 56 
11. 
DISTRIBUTION OF SERUM CREATININE IN 
CKD PATIENTS 57 
12. 
DISTRIBUTION OF SERUM CALCIUM IN CKD 
PATIENTS 58 
13. 
DISTRIBUTION OF SERUM PHOSPHOROUS IN 
CKD PATIENTS 59 
14. 
DISTRIBUTION OF LOW T3 AMONG VARIOUS 
LEVELS OF TSH 60 
15. DISTRIBUTION OF LOW T4 AMONG VARIOUS LEVELS OF TSH 
61 
16. ANALYSIS OF T3, T4, TSH EXCLUDING HYPOTHYROIDISM 
62 
17. ANALYSIS OF HYPOTHYROID SYMPTOMS IN CKD 
64 
18. ANALYSIS OF THYROID DYSFUNCTION IN THIS STUDY 
66 
19. DISTRIBUTION OF CREATININE CLEARANCE IN PATIENTS WITH LOW T3 SYNDROME 
67 
20. DISTRIBUTION OF CREATININE CLEARANCE IN PATIENTS WITH LOW T4 SYNDROME 
68 
21. AGE INCIDENCE OF LOW T3 SYNDROME 69 
22. SEX INCIDENCE OF LOW T3 SYNDROME 70 
23. CORRELATION OF THYROID HORMONES EXCLUDING HYPOTHYROIDISM 
71 
24. 
CORRELATION OF THYROID HORMONES 
WITH SEVERITY OF RENAL FAILURE 
EXCLUDING HYPOTHYROIDISM 
72 
25. INCIDENCE OF LOW T3 SYNDROME IN CKD 73 
 
 
 
  
LIST OF CHARTS 
SI. 
NO. TITLE 
PAGE 
NO 
1.  AGE WISE DISTRIBUTION OF CASES 51 
2.  SEX WISE DISTRIBUTION OF CASES 52 
3.  AGE/SEX DISTRIBUTION OF CASES 53 
4.  DURATION OF CKD SYMPTOMS  54 
5.  
DISTRIBUTION OF CREATININE CLEARANCE 
IN CKD PATIENTS 55 
6.  
DISTRIBUTION OF BLOOD UREA IN CKD 
PATIENTS 56 
7.  
DISTRIBUTION OF SERUM CREATININE IN 
CKD PATIENTS 57 
8.  
DISTRIBUTION OF SERUM CALCIUM IN CKD 
PATIENTS 58 
9.  
DISTRIBUTION OF SERUM PHOSPHOROUS IN 
CKD PATIENTS 59 
10.  
DISTRIBUTION OF LOW T3 AMONG VARIOUS 
LEVELS OF TSH 60 
11.  DISTRIBUTION OF LOW T4 AMONG VARIOUS 
LEVELS OF TSH 61 
12.  ANALYSIS OF T3, T4, TSH EXCLUDING 
HYPOTHYROIDISM 62 
13.  ANALYSIS OF HYPOTHYROID SYMPTOMS IN 
CKD 64 
14.  ANALYSIS OF THYROID DYSFUNCTION IN 
THIS STUDY 66 
15.  DISTRIBUTION OF CREATININE CLEARANCE 
IN PATIENTS WITH LOW T3 SYNDROME 67 
16.  DISTRIBUTION OF CREATININE CLEARANCE 
IN PATIENTS WITH LOW T4 SYNDROME 68 
17.  AGE INCIDENCE OF LOW T3 SYNDROME 69 
18.  SEX INCIDENCE OF LOW T3 SYNDROME 70 
19.  INCIDENCE OF LOW T3 SYNDROME IN CKD 73 
 
 
 
 
 
 
LIST OF FIGURE 
SI. 
NO. TITLE 
PAGE 
NO 
1. 
TSH STIMULATES IODIDE TRAP, 
THYROID HORMONE SYNTHESIS AND 
RELEASE 
6 
2. BIOSYNTHESIS AND SECRETION OF THYROID HORMONE 7 
3. KIDNEY 15 
4. GLOMERULAS AND BOWMANS CAPSULE 16 
5. STAGES OF CKD 20 
6. CLASSIFICATION OF CKD 20 
7. GFR CATEGORIES, DESCRIPTIONS, AND RANGES 23 
8. TYPES OF RENAL OSTEODYSTROPHY 29 
9. COMPLICATION OF CKD 33 
10. EFFECT OF THYROID HORMONES ON THE KIDNEY 35 
11. 
EFFECTS OF CHRONIC RENAL FAILURE 
ON HYPOTHALAMUS – PITUITARY – 
THYROID - AXIS 
41 
  
  
 
 
 
 
 
 
 
 
 
List of Abbreviations  
LIST OF ABBREVIATIONS 
 
CKD  - Chronic Kidney Disease 
ESRD - End stage renal disease 
GFR - Glomerular Filtration Rate 
DIT  - Diiodotyrosine 
MIT - Monoiodotyrosine 
T3  - Triiodothyronine 
T4   - Thyroxine 
rT3 - Reverse T3  
TRH  - Thyrotropin Releasing Hormone 
TSH - Thyroid Stimulating Hormone 
TBG - Thyroxine Binding Globulin 
HD  - Hemodialysis 
ACEI  - Angiotensin converting enzyme inhibitors 
ARB’s - Angiotensin receptor blockers 
NSAIDS  - Non steroidal anti inflammatory drugs 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 
1 
 
INTRODUCTION 
Chronic kidney disease includes a spectrum of distinct 
pathophysiological processes which is associated with abnormal kidney 
function and a progressive reduction in glomerular filtration rate1, 2. 
CKD is a clinical syndrome which occurs due to irreversible loss of 
renal function leading to metabolic, endocrine, excretory and synthetic function 
resulting in accumulation of non – protein nitrogenous substances which leads 
to metabolic derangements and ends up with distinct clinical manifestations. 
 End stage renal disease is described as a terminal stage of chronic 
kidney disease that without any replacement therapy patients could not survive 
would result in death. 
 In spite of diverse etiologies, CKD is the final common pathway of 
irreversible loss of nephrons finally resulting in alteration of “milieu interior” 
affecting every system in the body including thyroid hormonal system. 
The functions of thyroid and kidney are interrelated3-6. The thyroid 
hormones are essential for growth and development of the kidney and for 
maintaining electrolyte and water homeostasis. On the other hand, kidney has 
its vital role in metabolism and elimination of thyroid hormones. 
In CKD patients reduction of renal function leads to change in the 
synthesis, secretion, metabolism and elimination of thyroid hormone. And also 
treatment strategies of one organ affect the other organ. 
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The kidney helps in the clearance of iodine mainly by glomerular 
filtration. So excretion of iodine is reduced in advanced renal failure. Impaired 
renal clearance of iodine leads to elevated serum levels of inorganic iodide that 
potentially blocks thyroid hormone production resulting in “Wolff Chaikoff” 
effect. 
Chronic kidney disease is associated with thyroid function abnormalities 
leading to low levels of serum total and free T3 concentration and normal 
reverse T3 and free T4 levels. The TSH levels are almost normal in most 
patients and found to be in euthyroid state. 
CKD patients may have various symptoms and signs suggestive of 
hypothyroidism like cold intolerance, dry coarse skin, sallow complexion, 
lethargy, fatigue, edema, reduced basal metabolic rate, alopecia, hyporeflexia 
and asthenia. So it is difficult to exclude thyroid function abnormality in 
patients with chronic kidney disease merely on clinical background. 
Various studies have been conducted to study thyroid function 
abnormalities in chronic kidney disease patients. All abnormalities like 
hypothyroidism, hyperthyroidism and euthyroid state have been reported in the 
studies done previously. 
The relation between severity of renal failure and thyroid dysfunction is 
not clear. The estimated problem of hypothyroidism is between 0-9 percent in 
end stage renal disease. In ESRD increased prevalence of thyroid swelling 
(goitre) has also been noted. 
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In view of variability of thyroid profile in chronic kidney disease 
patients in previous studies, a prospective biochemical and clinical study on 
thyroid function has been undertaken in the department of medicine, 
Coimbatore medical college and hospital, Coimbatore. 
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AIMS & OBJECTIVES 
AIMS : 
To study the prevalence of low T3 Syndrome in Chronic kidney disease 
patients.  
 
OBJECTIVES : 
1. To study thyroid function abnormalities in patients with chronic kidney 
disease. 
2. To correlate the thyroid function abnormalities with severity of renal 
failure. 
3. To differentiate primary hypothyroidism from thyroid dysfunction due 
to chronic kidney disease. 
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REVIEW OF LITERATURE 
 
ANATOMY OF THYROID GLAND: 
The thyroid gland comprises two lobes united by an isthmus. It is 
situated in front of trachea between the suprasternal notch and cricoid cartilage. 
The thyroid gland weighs about 12 to 20 grams and is   bigger in females than 
in males. Four parathyroid glands are situated   back to each pole of thyroid 
gland, which secretes parathormone. 
  PHYSIOLOGY OF THYROID HORMONES: 
The principal hormones secreted by thyroid gland are T3 
(Triiodothyronine) and T4 (Thyroxine). Thyroid hormones play a vital role in 
cell differentiation during development and maintain metabolic homeostasis in 
adults9. The secretion of T3 and T4 are mainly controlled by Thyroid 
Stimulating Hormone. Thyrotropin releasing hormone (TRH) stimulates the 
secretion of T3 and T4. The hypothalamic secretion TSH and pituitary 
secretion of TRH are under negative feedback control of free T4 and free T3.6 
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FIGURE-1: TSH STIMULATES IODIDE TRAP, THYROID HORMONE 
SYNTHESIS AND RELEASE 
 The initial step in thyroid hormone synthesis is uptake of iodide. Then 
iodide trapping occurs by which iodide is actively transferred into thyroid cell, 
where it is “oxidised” to iodine. It then binds with tyrosine to produce 
monoiodotyrosine (MIT) and diiodotyrosine (DIT). 
 Coupling of MIT with DIT forms T3 whereas coupling of two DIT 
forms T4. Until secretion thyroid hormones T3 and T4 are in bound form with 
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thyroglobulin2-7. Thyroid peroxidase enzyme catalyzes oxidation, iodination 
and coupling reactions. 
 
FIGURE-2: BIOSYNTHESIS AND SECRETION OF THYROID 
HORMONE 
 Once the thyroid hormones are secreted into the blood, most of T3 and 
T4 binds with plasma proteins namely, thyroxine – binding globulin and 
thyroxine – binding prealbumin and albumin. T4 mainly binds with thyroxine – 
binding globulin whereas T3 binds mainly with albumin. The plasma binding 
proteins delays hormonal clearance, increases the circulating pool and helps in 
regulating hormonal delivery to selected tissue sites. The rest of the thyroid 
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hormones are transported in unbound form as free T3 and free T4. In 
circulation bound forms are in equilibrium with free forms.6, 7 
             In the periphery, the enzyme 5’ Deiodenase converts one-third of T4 to 
T3 and 5 deiodenase converts 45% of T4 to rT3. Only 13% of T3 is produced 
directly from thyroid gland, and the rest 87% is formed from T4. 
 Half life of T4 is longer than T3, whereas potency of T3 is longer than 
T4. The half life of T4 is seven days and T3 is 10 to 24 hours. 
 The rate of secretion of thyroxine is 80 to 90 micrograms/day, tri-
iodothyronine is 4 to 5 micrograms/day and reverse T3 is 1 to 2 
microgram/day. The plasma level of total T3 is0.12 microgram/dl and T4 is 8 
microgram/dl. 
HYPOTHYROIDISM 
 Hypothyroidism is caused by reduced secretion of thyroid hormones. 
It leads to cretinism in children and myxedema in adults. Hypothyroidism can 
be either primary or secondary. There is intrinsic defect in thyroid gland in 
primary hypothyroidism whereas it is secondary to hypothalamic or pituitary 
defect in secondary hypothyroidism. 
 The most common cause of hypothyroidism is low iodine content in 
the diet. In countries with adequate iodine in the diet the most common cause is 
autoimmune Hashimoto’s thyroiditis. The other causes include certain drugs, 
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previous thyroid surgery, and previous treatment with radioactive iodine, injury 
to hypothalamus or anterior pituitary gland. 
The symptoms of hypothyroidism includes8: 
 Tiredness 
 Weakness  
 Cold intolerance 
 Constipation  
 Dry coarse skin 
 Poor memory and difficulty in concentrating 
 Loss of hair 
 Weight gain 
 Breathlessness  
 Hoarseness of voice 
 Paresthesia 
 Reduced hearing 
 Menorrhagia  
Signs 
 Puffiness of face, hands and feet 
 Bradycardia  
 Cool peripheral extremities  
 Peripheral edema  
 Diffuse alopecia 
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 Delayed tendon reflex relaxation 
 Carpal tunnel syndrome 
 Serous cavity effusions. 
 The most important single biochemical parameter for screening 
hypothyroidism is TSH. TSH measurement in the normal range rules out the 
possibility of primary hypothyroidism but not the secondary. TSH level of > 20 
µIU/ml or if there is strong clinical suspicion level > 10 µIU/ml is necessary 
for diagnosing primary hypothyroidism. Along with raised TSH, there should 
be low free T4 level for diagnostic confirmation of hypothyroidism. Circulating 
free T3, though reduced in many, cannot be taken as reliable indicator because 
it is normal in 25% of hypothyroid patients 
TABLE – 1 DIFFERENCE BETWEEN PRIMARY AND SECONDARY 
HYPOTHYROIDISM 
Findings Primary Hypothyroidism 
Secondary 
hypothyroidism 
Skin Coarse Silky and soft 
Menstrual Cycle Excessive bleeding Amenorrhoea 
BP Increased or normal Decreased or normal 
Trans Cardiac diameter Increased Normal or decreased 
Serum TSH Increased Decreased 
Serum Cholesterol Increased  Not altered 
Abnormality of other 
pituitary hormones Not seen 
Seen 
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HYPERTHYROIDISM: 
 Hyperthyroidism is a condition resulting from elevated free thyroid 
hormone level on the body tissues. The major cause includes Graves Disease, 
Toxic Multi nodular Goitre, and Solitary thyroid nodule. 
Symptoms: 
 Intolerance to heat 
 Sweating 
 Hyperactivity, Irritability 
 Dysphonia 
 Palpitation 
 Fatigue, Weakness 
 Weight loss in spite of increased appetite 
 Oligomenorrhoea 
 Loss of libido 
 Polyuria 
 Diarrhoea  
Signs: 
 Tremors 
 Warm moist skin 
 Tachycardia 
 Atrial fibrillation in elderly 
 Goitre 
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 Proximal Myopathy 
 Muscle weakness 
 Apathetic thyrotoxicosis is a condition seen in elderly in whom the 
features of thyrotoxicosis are subtle or masked, the patients present mainly with 
weight loss and fatigability.  
 In hyperthyroidism, TSH level is reduced, total and free T3 T4 levels 
are increased. 2 to 5 % of patients show isolated T3 increase, a condition called 
as ‘T3 Thyrotoxicosis’ while total and free T4 increase with normal T3 is 
called ‘T4 Thyrotoxicosis’ 
Non Thyroidal Illness: 10-15 
 Various conditions predominantly affect serum T3 level, with no 
intrinsic disease of Thyroid gland. This is termed as ‘Low T3 Syndrome’, ‘Non 
Thyroid Illness syndrome’, ‘Sick euthyroid syndrome’. 
The conditions include 
 Trauma 
 Burns 
 Acute Critical illness 
 Acute Febrile Illness and infections, 
 Acute myocardial infarction 
 Surgery 
 Fasting 
13 
 
 Diabetes Mellitus 
 Renal Disease 
 Liver Disease 
 Ketogenic Diet 
 Malignancy 
 Certain Medications 
1. Glucocorticoids 
2. Beta blockers 
3. Dopamine 
4. Phenytoin 
5. Others  
 Psychiatric illness 
 In non thyroid illness, fall in serum T3 level (both total and free T3) 
along with raise in reverse T3 is seen. As disease progresses, fall in serum total 
T4 is also seen, a condition called ‘low T3 T4 State’. Free T4 remains normal 
or reduced. Although there is fall in T3 and T4, serum TSH remains either 
normal or reduced which differentiates it from primary hypothyroidism. Many 
studies have shown that there is mild elevation of TSH in absence of 
hypothyroidism in non-thyroidal illness7,22,35,36,37,38. 
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TABLE -2  CONDITIONS CAUSING NON-THYROIDAL ILLNESS 
Conditions 
Serum Serum Serum Serum Serum  
T3 rT3 T4 Free T4 TSH 
 
 
Fasting Decreased Increased No change No change Decreased  
Mild illness Decreased Increased No change 
No change/ 
increased 
No change 
 
 
 
Critical 
Illness 
Decreased Increased Decreased 
No change/ 
decreased 
Decreased 
 
 
 
Surgical 
trauma, burns 
Decreased Increased Decreased Decreased 
No change/ 
Decreased 
 
 
 
Chronic renal 
Failure 
Decreased No change 
No change/ 
decreased 
No change/ 
decreased 
No change/ 
Decreased 
 
 
Hepatitis 
No change/ 
Increased 
No change/ 
increased 
No change/ 
increased 
No change/ 
decreased 
No change 
 
 
 
HIV infection No change Decreased No change 
No change/ 
decreased 
No change/ 
Increased 
 
 
 
Depression 
No change/ 
Decreased 
No change/ 
Increased 
No change/ 
Increased 
No change/ 
Increased 
No change/ 
Decreased  
 
 NORMAL KIDNEY:
 The kidneys are bean shaped paired retroperitoneal organs located in 
the lumbar region in the posterior part of the abdomen on either side of the 
vertebral column. The upper pole of each kidney lies opposite the 12
vertebra16 and the lower pole of each kidney lies opposite the third lumbar 
vertebra. The weight of eac
155 grams in females
breadth is about 5.0 to 7.5 cms, and thickness is about 2.5 to 3.0 cms.
 
 
  
 
 
 
 
 
 
15 
 33, 34 
h kidney is about 125 to 170 grams in male 115 to 
16
. The length of each kidney is about 11 to 12 cms, 
FIGURE-3: KIDNEY 
th
 thoracic 
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 Nephrons are the structural and functional unit of the kidney. 0.4 to1.2 
million16 nephrons are present in each kidney. The Glomerulus and Bowman’s 
capsule are the filtering area of nephrons. Glomerulus is a cluster of capillaries 
formed from afferent arteriole and ends in efferent arteriole. The dilated blind 
end of the nephrons is Bowman’s capsule.   
 
 
 
 
 
 
 
 
 
 
FIGURE-4: GLOMERULUS AND BOWMANS CAPSULE 
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 The capillary endothelium and epithelium of Bowman’s capsule 
which is made of podocytes, separates the blood flowing in glomerulus from 
bowman’s space.  
 The pars convoluta and pars recta constitute the proximal segment of 
the nephrons. The convoluted portion drains into           —› straight sinus —› 
loop of Henle. Henle’s loop comprises the descending limb, thin segment and 
the ascending limb.  
 The pars recta (straight portion) constitute the distal segment of the 
nephrons. The ascending limb of Henle’s loop continues as the distal segment. 
It then drains into collecting tubules. The collecting tubule finally ends into the 
collecting duct. 
BLOOD SUPPLY 
 The blood supply of each kidney is derived from renal arteries which 
arise from abdominal aorta at the level of 2nd lumbar vertebra. The renal 
arteries before entering the renal hilus, divides into five segmental arteries to 
supply five vascular segments of kidney. 
The segmental arteries then ultimately divide into arcuate arteries which 
further subdivide into intralobular arteries.  The intralobular arteries then give 
rise to afferent arteriole which forms the glomerular tuft. 
Glomeruli end with efferent arteriole which then forms peritubular 
capillaries and ends up in intralobular vein. In juxtamedullary nephrons vasa 
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recta are formed from peritubular capillaries before becoming intralobular 
veins. 
FUNCTIONS OF THE KIDNEY 
The major functions of the kidney includes  
 Excretion of metabolic waste products, toxins and some drugs. 
 Regulation of fluid and electrolyte balance. 
 Regulation of acid – base balance. 
 Regulation of body fluid osmolality and electrolyte composition. 
 Regulation of blood pressure. 
       It also plays a vital role in secretion, metabolism and excretion of 
hormones. Its major endocrine function includes production of erythropoietin, 
renin, prostaglandins and endothelins. 
 The major metabolic function of the kidney includes 1hydroxylation of 
25 hydroxy D3 and helps in vitamin D synthesis. It helps in regulation of 
erythrocyte production by secreting erythropoietin. 
DETERMINANTS OF GFR18 
 Cockcroft and Gault formula is used in estimating GFR.  
Estimated creatinine clearance in ml/min = (140 – age) X Lean body 
weight (kg) 72X plasma creatinine (mg/dl) Multiply by 0.85 for women. 
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CHRONIC KIDNEY DISEASE17 
Definition  
 Evidence of kidney damage for more than or equal to three months as 
described by anatomical or physiological abnormalities of the kidney, 
with or without reduced GFR. 
 GFR less than 60 ml/min/1.33m2 for more than or equal to three months 
with or without other signs of kidney damage. 
Causes of chronic kidney disease 
 The most common cause of chronic kidney disease in developed 
countries is diabetic glomerulosclerosis whereas in developing countries 
primary glomerulonephritis is the leading cause. 
MAJOR ETIOLOGIES OF CKD 
 Diabetic nephropathy 
 Glomerulonephritis 
 Hypertension – associated CKD 
 Autosomal dominant polycystic kidney disease 
 Tubulointerstitial nephropathy 
 Medullary cystic diseases 
 Others 
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Stages of CKD17 
 
FIGURE-5: STAGES OF CKD 
 
FIGURE-6: CLASSIFICATION OF CKD 
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TABLE 3. CLASSIFICATION OF CKD 
Classification of chronic kidney disease by pathology and etiology 
Pathology Etiology 
1.Diabetic glomerulosclerosis 
2.Glomerular diseases (primary or 
secondary) 
 
 Proliferative glomerulonephritis 
 
 
 
   Minimal change disease 
   Focal glomerular sclerosis 
   Membranous nephropathy 
   Fibrillary glomerular diseases 
   Hereditary nephritis  
Diabetes mellitus (type 1&2) 
Largely unknown 
 
Systemic lupus erythematous, 
Vasculitis, hepatitis B or C, human 
immunodeficiency virus (HIV) 
bacterial endocarditis 
Hodgkin’s disease 
HIV, heroin toxicity 
Drug toxicity, solid tumours  
Amyloidosis, light chain disease 
Alport’s syndrome 
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3.Vascular diseases 
   Diseases of large size vessels 
   Diseases of medium size 
   vessels (nephrosclerosis) 
   Diseases of small vessels    
(microangiopathy) 
4.Tubulointerstital diseases 
   Tubulointerstitial nephritis 
   Reflux nephropathy 
   Obstructive nephropathy 
   Myeloma kidney 
5. Cystic diseases 
   Polycystic kidney disease 
   Tuberous sclerosis 
   Von – Hippel – landau disease 
   Medullary cystic disease 
Renal artery stenosis, aortoarteritis 
Hypertension 
 
Haemolytic uraemic syndrome, 
vasculitis, sickle cell disease. 
 
Infections, drugs, sarcoidosis  
Vesico – ureteric reflux 
Stones, prostatism, malignancy 
Multiple myeloma 
 
Autosomal dominant or recessive 
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FIGURE-7: GFR CATEGORIES, DESCRIPTION AND RANGES. 
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PATHOPHYSIOLOGY 
 The two extents of mechanisms of kidney damage involved in 
pathophysiology of CKD include: 
1. Initiative mechanisms which is definite to the underlying etiology. 
2. Progressive mechanisms, involving hyperfiltration and hypertrophy of 
remaining viable nephrons following long term reduction of renal mass, 
regardless of underlying etiology. 
The mediators for nephron loss are  
 Cytokines  
 Growth factors  
 Vasoactive hormones 
At last, short term adaptations of hypertrophy and hyperfiltration 
becomes maladaptive as the pressure increases and flow within the nephron 
susceptible to glomerular architectural distortion, podocyte dysfunction and 
interruption of filtration barrier which leads to sclerosis and dropout of 
remaining viable nephrons. Increased renin- angiotensin system contributes to 
both initiative and subsequent maladaptive hypertrophy and sclerosis. 
The unique property of kidney in CKD is compensatory and adaptive 
mechanism which maintains acceptable health until the GFR falls to 10 to 15 
ml/minute and life sustaining renal excretory and homeostatic functions 
continues until GFR is less than 5 ml/minute. 
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INTACT NEPHRON HYPOTHESIS 
 In CKD patients, there is progressive loss of functioning nephrons. The 
remaining few viable nephrons compensate for nephron loss and tends to 
hypertrophy which results in increased work load, so overall functional loss is 
reduced. This adaptive mechanism is known as compensatory hyperfiltration. 
 A study conducted in renal transplant donors, there is 40% increased in 
glomerular filtration and renal plasma flow in the remaining kidney within 
weeks after nephrectomy. The GFR increases to about 70% of prenephrectomy 
value. 
 Increased perfusion of remaining viable nephrons leads to produce 
increased volume of filtrate. The tubules respond to these changes by excreting 
fluids and solutes in amounts which helps in maintaining external balance. This 
close integration of functions of glomerulus and tubules is known as 
“glomerulotubular balance” which is preserved till late stages of CKD. 
TRADE OFF HYPOTHESIS 
Trade off hypothesis states that, adaptation emerging in CKD may 
control one abnormality, but only in such a way to produces other changes 
characteristics of uraemic syndrome. The mechanism of which is not known. It 
is described in hormones like atrial natureteric peptide, parathormone, 
vasopressin and solutes like sodium, potassium, phosphate and others. 
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MIDDLE MOLECULE HYPOTHESIS19 
 In patients treated with maintenance peritoneal dialysis, there is conflict 
between the degree of azotemia and severity of symptoms. Inspite of high renal 
parameters symptoms of uraemia are mild in patients with maintenance 
peritoneal dialysis and they are less prone for developing features of peripheral 
neuropathy when compared with patients on hemodialysis. 
 These above mentioned features suggest that toxicity  is mainly related 
to accumulation of substances with high molecular weight. These toxic 
substances are cleared more readily with maintenance peritoneal dialysis than 
by hemodialysis. Comparing to hemodialysis membrane, the peritoneal dialysis 
membrane are more permeable to solutes of middle molecular weight (50 to 
500 daltons).  
FLUID, ELECTROLYTES AND ACID BASE DISORDERS  
Sodium and water homeostasis  
 In CKD patients, extracellular fluid volume is maintained in the normal 
range till the very late stages of CKD. Fractional excretion of sodium increases 
in patients with CKD so that absolute sodium excretion is not changed until 
late changes. 
Total body content of sodium is major determinant of extracellular fluid 
volume, so any interruption in sodium balance will causes volume overload or 
volume depletion. Volume depletion is mainly due to abrupt salt restriction in 
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CKD patients, which is mainly seen with tubulointerstitial diseases (salt losing 
nephropathies). Volume overload is mainly due to retention of sodium which 
leads to peripheral edema, arterial hypertension and cardiac failure. 
Diuretics are used to force natriuresis in CKD patients. Thiazide 
diuretics have a little role, higher doses of loop diuretics are recommended in 
CKD. Loop diuretics can be combined with metalazone, which inhibits sodium 
chloride co–transporter present in the distal convoluted tubule of the kidney, 
promoting increased sodium excretion. 
Potassium homeostasis 
 In CKD, potassium excreting capacity of kidneys is reduced which is 
proportional to loss of glomerular filtration. The adaptive mechanisms are 
stimulation of aldosterone and increasing extrarenal (intestinal) excretion of 
potassium to maintain potassium homeostasis until the glomerular filtration 10 
ml/minute. 
 The cause of hyperkalemia in CKD patients is mainly due to drugs such 
as ACEI, ARB’s, NSAIDS, aldosterone antagonist. The other causes include 
diet rich with potassium, haemorrhage, hemolysis, protein breakdown, 
metabolic acidosis. Hyperkalemia is treated with dextrose with insulin, 
salbutamol nebulisation, 10% calcium gluconate (if electrocardiographic 
changes are seen). 
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 Hypokalemia is rare in CKD, if it present it is mainly seen with 
excessive diuretic therapy, extrarenal (gastrointestinal) loss, reduced intake of 
potassium. 
Metabolic acidosis  
 In earlier stages of CKD non anion gap metabolic acidosis is mainly 
seen. In advanced stages of CKD, the net daily total urinary acid excretion is 
limited to 30 – 40 mmol and anion gap of not more than 20mEq/L is seen 
generally. 
Haematological changes20 
 In CKD there is reduced renal synthesis of erythropoietin, a hormone 
involved in stimulation of bone marrow red blood cell production, as a result 
normocytic normochromic anaemia occurs.  
 The other causes of anaemia in CKD includes  
 Shortened RBC survival time 
 Iron deficiency  
 Vitamin B12 and folate deficiency  
 Uraemia induced platelet dysfunction and bleeding  
 Aluminium toxicity  
 Chronic inflammation  
 Renal osteodystrophy and bone marrow fibrosis 
 
 Bone Changes21 
 Disorders of mineral metabolism in CKD 
resulting in both skeletal and extraskeletal manifestations.
Mineral and bone metabolism disorder in CKD manifests as:
 Abnormalities of calcium, phosphorous, parathormone and vitamin D 
metabolism. 
 Abnormalities of bone turn 
 Vascular and soft tissue calcification.
Renal osteodystrophy 
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PATHOGENESIS  
High turnover bone disease 
 Secondary hyperparathyroidism in CKD is the cause for high turnover 
bone disease. In the early stages of CKD, there will be parathyroid gland 
hyperplasia and increased levels of parathormone in blood. These changes are 
caused by hypocalcemia, hyperphosphatemia, reduced synthesis of calcitriol, 
parathormone resistance, and intrinsic alterations in parathyroid gland. 
Low turnover bone disease  
 Low turnover bone disease is characterised by depressed bone formation 
which is mainly seen in patients on dialysis. Osteomalacia can also occur 
mainly due to accumulation of aluminium at bone surfaces. Aplastic bone 
disease can be seen even before dialysis. 
Mixed osteodystrophy  
 It includes features of both high turnover bone disease and low turnover 
bone disease. 
CKD AND HEART 
 In CKD, the leading cause of morbidity and mortality is cardiovascular 
diseases. Myocardial ischemia, left ventricular hypertrophy and uraemia (salt 
and water retention) which occur in CKD results in congestive cardiac failure 
and pulmonary edema, due to increased permeability of alveolar capillary 
membrane. 
31 
 
Uraemic encephalopathy  
 It may present as acute or subacute organic brain syndrome when 
glomerular filtration declined to less than 10% of normal. That clinical 
presentation of uraemic encephalopathy includes altered consciousness, 
psychomotor disturbances, and disorders of thinking, memory, speech, 
perception and emotion. 
Peripheral neuropathy  
 The classical features of peripheral neuropathy are seen in advanced 
stages (stage IV and V) of CKD. The involvement of sensory neuropathy is 
more common than motor neuropathy. The lower extremities are more involve 
than upper extremities and distal part of limb is more involved than proximal 
part. 
Restless leg syndrome  
The restless leg syndrome is one of the treatable causes of sleep 
disruption in end stage renal disease. It is a neurological movement disorder of 
limbs associated with sleep disturbances. It is characterised by unpleasant 
sensation in legs and feet requiring frequent limb movement. The urge to move 
limbs is more during rest and can be relieved with movements. 
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Gastrointestinal abnormalities   
 Uraemic gastritis, peptic ulcer disease and mucosal ulcerations can be 
seen anywhere in the gastrointestinal tract in patients with chronic kidney 
disease. 
Metabolic disturbances 
Fasting hyperinsulinemia and tendency to spontaneous hypoglycemia  
are seen in patients with end stage renal disease . Insulin requirement may be 
reduced in late stages of CKD. The other abnormalities seen are impaired 
glucose tolerance and reduced insulin sensitivity. 
Dermatological abnormalities  
 The common dermatological abnormalities seen in CKD  include 
pruritis and skin excoriation. Abnormal calcium and phosphorus metabolism 
can lead to vascular and soft tissue calcification which results in skin and soft 
tissue necrosis. It is known as calciphylaxis seen mainly due to secondary 
hyperparathyroidism. 
 
 FIGURE
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THYROID AND KIDNEY 
 Thyroid hormones play a vital role in renal development and 
physiology39,40,41,42,43. On the other hand kidney disease can lead to thyroid 
dysfunction. 
Effects of thyroid hormone on renal development: 
 It helps in protein synthesis and cell growth. The functioning renal mass 
(kidney to body mass ratio) is affected by thyroid hormone. In hypothyroidism 
the ratio is reduced, increased in hyperthyroidism whereas protein breakdown 
and ultimately renal atrophy occurs in severe hyperthyroidism44. Thyroid 
hormone increases the activity of Na-P co-transporter49, Na-H exchanger50 and 
Na/K ATPase51 in the proximal convoluted tubule. 
Effect of thyroid hormone on renal physiology: 
 Thyroid hormones have both direct and indirect effects on renal 
function. The indirect effect is mediated on cardiovascular system and renal 
blood flow. The direct effects are mediated on glomerular filtration rate, 
tubular secretory and reabsorptive function and hormonal influences. 
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FIGURE-10: EFFECTS OF THYROID HORMONES ON                                
THE KIDNEY. 
 The thyroid hormone increases the activity of Na/K/ATPase on 
proximal convoluted tubule and also increases sodium reabsorption. Thyroid 
hormones also influences on tubular potassium permeability52 and tubular 
calcium reabsorption53. By adrenergic regulation54 thyroid hormones also affect 
the renin angiotensin aldosterone axis and helps in renin release55. 
  
THYROID HORMONE 
 
GROWTH 
 
DEVELOPMENT 
RENAL 
PHYSIOLOGY 
Metabolic effects 
Increase sodium tubular reabsorption 
 Stimulate renin secretion 
 Control sulfate homeostasis 
  Increase calcium tubular reabsorption 
36 
 
TABLE 4. EFFECT OF THYROID DYSFUNCTION ON THE KIDNEY 
 Hypothyroidism Hyperthyroidism 
Serum creatinine Increased Decreased 
Glomerular filtration Decreased Increased 
Renal plasma flow Decreased Increased 
Sodium reabsorption Decreased Increased 
Hypothyroidism and Renal function  
 In hypothyroidism there will be increases serum creatinine level 45,46,47  
reduced glomerular filtration and renal plasma flow. The direct effect of 
thyroid hormone on cardiovascular system produces increased peripheral 
vascular resistance, diminished myocardial contractility and stroke volume and 
its effect on metabolism causes hyperlipidemia. The indirect effects of thyroid 
hormones are mediated through insulin like growth factor type I and vascular 
endothelial growth factor63. 
 The commonest electrolyte abnormality seen in hypothyroidism is 
hyponatremia. It is primarily due to reduced GFR, producing decreased water 
delivery to distal tubules. The other possible cause is inappropriate ADH 
secretion.  
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 The proximal tubular reabsorption sodium, chloride and water are 
reduced65. The pathological changes such as glomerular basement membrane 
thickening and mesangial matrix expansion are seen in hypothyroidism64 which 
leads to diminished renal blood flow. 
 The sensitivity of collecting duct to vasopressin receptor is increased 
reversibly, thus increasing free water reabsorption. There is diminished 
production of Cystatin –C, so that serum levels of Cystatin – C is reduced in 
hypothyroidism62. Most of the above mentioned changes are reversible with 
treatment of hypothyroidism with levothyroxine.  
Hyperthyroidism and renal function 
 Thyroid hormones have positive chronotrophic57, inotrophic58 effect and 
also decrease systemic vascular resistance59 which indirectly contributes to 
increase in renal blood flow. 
 The other indirect effects of thyroid hormones to increase renal blood 
flow are by increasing endothelial production of nitric oxide60 along with 
reduction in endothelin, a renal vasoconstrictor. 
 In hyperthyroidism GFR increases by about 18 – 25%56, this is due to 
increase renal blood flow. There is increased beta adrenergic activity and 
increased stimulation of renin angiotensin aldosterone system61 due to 
hyperthyroidism. The increased renin angiotensin aldosterone activity produces 
afferent arteriolar vasodilatation and efferent arteriolar vasoconstriction which 
consequently produces increased glomerular filtration rate (GFR). 
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 In hyperthyroidism there is accentuated activity of apical Na-H 
exchanger50, basolateral Na/K/ ATPase48, Na – Pi co-transporter49. 
 In hyperthyroidism serum creatinine is significantly reduced due to 
increased glomerular filtration and reduction in overall muscle mass61. Due to 
glomerular hyperfiltration there is increase in 24 hour – urinary protein44. 
CKD and thyroid function abnormalities 
  Hyperthyroidism accelerates the CKD by various mechanisms which 
includes, 
• It results in intraglomerular hypertension which produces increased 
filtration pressure and consequent hyperfiltration. 
• It predisposes to proteinuria which causes direct renal injury66.  
• Down regulation of superoxide dismutase and increased mitochondrial 
energy metabolism contributes to free radical generation and subsequent 
renal injury. 
• Oxidative stress. 
The earliest thyroid dysfunction seen among chronic kidney disease patients is 
low T3 level (particularly total T3 than Free T3)67. This is known as low T3 
syndrome. 
Low T3 syndrome occurs in CKD due to  
1. Chronic metabolic acidosis 
2. Fasting  
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3. Protein malnutrition  
4. Reduced peripheral conversion of T4 to T3 
5. Iodothyronine deiodination 
The inflammatory cytokines such as tumor necrosis factor alpha (TNF 
alpha) interleukin – 1 (IL -1) In CKD patient inhibits the expression' of enzyme 
type 1 5’ deiodinase, which is necessary for peripheral conversion of T4 to T3. 
There is increased serum iodine level due to impaired renal handling, 
causing a Wolff – Chaikoff effect68. 
There is reduced iodide excretion resulting in elevated serum iodide 
level and iodine content of thyroid gland which consequently produces 
enlargement of thyroid gland. There is increased prevalence of thyroid nodule, 
goitre, thyroid carcinoma in chronic kidney disease patients when compared to 
general population78. 
The CKD patients on haemodialysis have low levels of thyroid 
hormones and elevated TSH. Though there is reduction in total T4 level due to   
heparin induced impaired protein binding, there will be increased free T4 
fractions seen in patients after heparin dialysis69. 
In patients on peritoneal dialysis, there is raised prevalence of low T3 
level and subclinical hypothyroidism70. T3, T4, thyroxine binding globulin 
(TBG) are lost in the peritoneal dialysis effulent. 
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The CKD mediated thyroid function abnormalities are recovered after 
renal transplantation71. Within the first three to four months low T3 and low T4 
levels recovers after kidney transplantation. 
Other renal diseases associated with thyroid dysfunction 
 Membranous nephropathy72,73. 
 Ig A nephropathy74. 
 Membranous proliferative glomerular nephritis75.  
 Minimal change disease76. 
 Tubulointerstitial nephritis and uveitis77. 
PATHOPIIYSIOLOGY OF LOW T3 SYNDROME 
 In CKD patients there is initial decrease in Total T3, later T4 in spite of 
low or normal TSH.7,22 There are several mechanisms that have been proposed 
for the change in thyroid profile in CKD. 
According to the postulates, CKD can affect the thyroid economy at all 
the levels as follows 
 
 
 
 
 
41 
 
 
 
 
 
    
    
 
 
 
 
 
 
 
 
FIGURE-11: EFFECTS OF CHRONIC RENAL FAILURE ON 
HYPOTHALAMUS-PITUITARY-THYROID AXIS 
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Reduced T3 conversion from T4 
Eleva 
tion of free T4 induced by heparin in HD 
Normal total rT3 and elevated free rT3 
Alteration in binding proteins 
Reduced T4 response to exogenous TSH 
Reduced iodide renal excretion 
Chronic Renal Failure  
42 
 
1. Changes in Hypothalamic — pituitary — thyroid axis  
 There is decreased sensitivity of TSH secretion in response to low 
thyroid hormone. 
 The TSH reserve is limited.13 
 Reduced nocturnal pulses of TSH secretion Due to changes in 
thyrotrophs or to decreased secretion of TRH.15,23,26 
 Tissue concentration of the thyroid hormone may be appropriate, so the 
patient is in euthyroid state.13 
 Serum Free T3 and Free T4 appears normal by sensitive methods24,25 
.2. Changes in hormonal Transport  
 The binding of thyroxine with thyroxine binding globulin is prevented 
by presence of protein and non protein inhibitors. Non esterified 
unsaturated fatty acid is non protein inhibitor.15,29 
 There is acquired intrinsic structural alternation in the T4 binding site30 
 Reduced concentration of thyroxine binding globulin.13,15 
3. Changes in metabolism  
 Decreased activity of lodothyronine 5 — Deiodinase is seen, resulting in 
low T3.13,15 
 There is increase in Non-deiodinative pathways of iodothyronine 
degradation resulting in increased serum T3 sulphate, diiodotyrosine, 
triiodo thryoacetic acid and tetraiodothyroacetic acid.13,15 
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As already mentioned,  there  is  no net  increase  of  reverse T3  in  CKD  
patients due  to redistribution of rT3 into extra vascular compartment13,15 
4. Changes in plasma membrane Transport 
The thyroid hormones T3 and T4 enter cells not only by diffusion but 
also by active energy dependent transport across plasma membrane. 
Accumulation of certain substances in blood of CKD patients prevents 
uptake and subsequent deiodination. 
The substances are 
A. 3 — carboxy 4— methyl 5 — propyl 2— Furane (CMPF)  
B. Indoxyl sulphate  
In uraemia there is no compromise in the action of thyroid hormones at 
nuclear level. Recent study also shows that there is increased receptor 
expression to preserve tissue euthyroidism state.31  
DIAGNOSIS OF PRIMARY THYROID DISEASES IN  
Recent studies have shown that there is increase in the prevalence of 
hypothyroidism in chronic kidney disease9. Since several clinical features of 
both hypothyroidism and chronic kidney disease are found to be similar, there 
are several difficulties in differentiating both the conditions on clinical 
background alone. So, all the CKD patients with symptoms suggestive of 
hypothyroidism should have to be screened for hypothyroidism. 
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The diagnosis of hypothyroidism should be made only if the following 
criteria exist: 
 There should be an elevation of basal TSH value of > 20 µIU/m1.  
 The both total and free T4 level should be distinctly low in the presence 
of normal TBG31.  
 Presence of anti thyroid antibodies can provide clue for 
hypothyroidism.31 
 Reverse T3 is not so useful because it is reduced in CKD.  
In CKD primary hyperthyroidism is very rare. This condition should be 
diagnosed with 
 High serum total and free T4 concentration. 
 Low serum TSH values  
High serum T4 level with low T3 in the presence of CKD should make the 
possibility of T4 thyrotoxicosis. This is due to suppression of serum T3 level in 
low T3 syndrome but serum T4 remains unaffected15. 
MANAGEMENT 
There are several studies which have been conducted in patients with the 
Low T3 syndrome in order to correct the thyroid profile by treating with 
Levothyroxine32 and Triiodothyronine25. 
Gregory Brent et al32 conducted a study in non thyroidal illness patients. 
They treated all the patients with serum total T4 less than 5 tg/dl with 1.5 
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jig/Kg of levothyroxine for 2 weeks. There is significant increase in thyroxine 
level in treated patients.  
There is also significant rise in serum T3 levels. But increased mortality 
was seen in the treatment group on day 5-17. 
Carter et al25 studied effects of administration of Triiodothyronine in the 
patients with CKD. The study showed that there is no change in serum T3 level 
over a period of 12 weeks. The mean serum T4 and TSH levels were affected 
significantly. But there was no subjective improvement seen in this group of 
patients. 
Based on above observations, it has been suggested that low serum T3 
level in patients with CKD is metabolically protective and it is interpreted as 
physiological adaptation to a reduced basal metabolic rate (BMR) and to 
conserve energy in an adverse environment. Because of that, this condition has 
been renamed as “Thyroid hormone adaptation syndrome”.15 
There is suppression of TSH level and increased catabolism, are seen on 
administration of T4 or T3. Hence, administration of thyroid hormone is not 
beneficial in patients with CKD. The study also shows there is increase in 
mortality with the treatment. So, thyroid hormone replacement should not be 
provided in CKD patients unless true hypothyroidism can be documented. 
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PROGNOSIS  
The magnitude of the thyroid function abnormalities that occurs in 
patients fulfilling the criteria for chronic kidney disease, in general reflects the 
severity of the illness22. The prognosis is bad in patients with low levels of 
serum T3 and T4 or TSH concentration. Studies have shown that there is 
reverse of thyroid function abnormalities in CKD patients after renal 
transplantation. 
  
  
 
 
 
 
 
 
 
 
 
Materials & methods 
47 
 
MATERIALS AND METHODS 
Source of data 
Patients who were on conservative management fulfilling the criteria for 
chronic kidney disease admitted in Department of Medicine, Coimbatore 
medical college & hospital, Coimbatore. 
Methods of collection of data 
Study subjects:  
The present study is conducted on 50 patients, who are diagnosed to 
have chronic kidney disease and on conservative management, being admitted 
in Department of Medicine, Coimbatore medical college & hospital, 
Coimbatore, during the period of July 2014 to July 2015. These samples are 
selected by using simple random sampling method. Statistical parameters such 
as mean, standard deviation (SD) and correlations are used, and parametric and 
non parametric tests are used for the analysis. 
Informed consent was obtained from all the patients. 
Study design: An observational, cross sectional 
Inclusion criteria: 
 Patients with chronic kidney disease. 
Patients who fulfill the criteria for CKD and who were on conservative 
management. 
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Criteria for Chronic Kidney Disease 
1. Presence of uraemic symptoms for 3 months or more  
2. Raised blood urea, serum creatinine and reduced creatinine clearance.  
3. Ultra sonogram evidence of chronic kidney disease  
• Bilateral contracted kidneys — size less than 9 cm. 
• Poor cortico-medullary differentiation. 
• Supportive laboratory evidence of CKD like anaemia, changes in 
serum electrolytes, etc.,  
Exclusion criteria 
1. Patients on peritoneal dialysis or hemodialysis  
2. Nephrotic range of proteinuria  
3. Hypoalbuminemia 
4. Other conditions like  
• Acute illness  
• Diabetes mellitus  
• Recent surgery 
• Trauma  
• Burns  
• Liver diseases  
• Drugs altering thyroid profile like amiodarone, phenytoin, 
beta-blocker, dopamine, steroids, estrogen pills and iodine-
containing drugs.  
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 Detailed history and clinical examination were undertaken in patients 
with CKD and who were on conservative management with preference to renal 
and thyroid diseases. The following investigations were done. 
• Urine routine and microscopic examinaition. 
• Peripheral smear for anaemia 
• Blood  urea 
• Serum Creatinine  
• Creatinine clearance (using Cockcroft — Gault formula)  
• Serum electrolytes  
• Serum calcium, phosphorous and uric acid 
• Serum cholesterol  
• 24 hours urinary protein  
• Serum protein (Total protein / albumin / globulin) 
• USG abdomen for evidence of chronic kidney disease  
After selection of patients, fulfilling the above criteria, about 5 ml of 
blood sample is collected in non-heparinised serum bottle and sent for thyroid 
profile test. 
Components of thyroid profile included in our study 
 Serum Triiodothyronine (T3)  
 Serum thyroxine (T4)   
 Serum thyroid stimulating hormone (TSH)  
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Quantitative determnation of T3, T4 and TSH is done by Enzyme Linked 
Immunosorbent Assay. 
THYROID PROFILE NORMAL RANGE 
Total T3 0.6 to 2.1 ng/ml 
Total T4 5 to 13 micro gram/dl 
TSH 0.4 to 7 micro IU/ml 
                            
 
 
 
 
 
 
 
 
                                                
  
 
 
 
 
 
 
 
 
 
Results and analysis 
  In our study 50 patients of CKD who were on conservative management 
fulfilling the criteria for CKD were studied, among these 34 were males and 16 
were females, their age varied from 20 
TABLE 
 
Age(Years)
<30
30 – 60
>60
Total
CHART 
Among the 50 patients in our study, patients who were 30 years old and 
below were 9 constituting 18%, between 31 
70% and 60 years of age and above were 6 in number constituting 12%.
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RESULTS AND ANALYSIS 
- 68 years.  
– 5: AGE DISTRIBUTION OF CASES
 
Total 
Number Percentage
 9 18%
 35 70%
 6 12%
 50 100%
– 1 - AGE DISTRIBUTION OF CASES
- 60 years were 35 
18%
70%
12%
AGE
<30 30 – 60 >60
 
 
 
 
 
 
 
 
constituting 
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TABLE – 6 – SEX DISTRIBUTION OF CASES 
 
CHART – 2 – SEX DISTRIBUTION OF CASES 
 
Among the 50 patients study, 68% of patients were males and 32% 
patients were females. 
  
68%
32%
0%
Chart Title
MALE FEMALE
SEX 
 
TOTAL MALE FEMALE 
34 16 50 
68% 32% 
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TABLE – 7 – AGE/ SEX DISTRIBUTION OF CASES 
 
Age(Years) 
Sex Total 
Male Female Number Percentage 
<30 8 1 9 18% 
30 – 60 23 12 35 70% 
>60 3 3 6 12% 
Total 34 16 50 
 
Mean age of males 43.5+13.49 
Mean age of females 48+13.47 
‘t’= 1.1, p= >0.05 (Not significant) 
CHART – 3 – AGE / SEX DISTRIBUTION OF CASES 
 
0 5 10 15 20 25
<30
30-60
>60
AGE/SEX DISTRIBUTION 
FEMALE
AGE/SEX DISTRIBUTION MALE
 TABLE
Duration of symptoms
(Months)
0
7-
13
19
25
Total
CHART 
In our study the duration of symptoms of CKD ranges from 4 months to 
30 months, while most were in the 7 
being 9.84 months. 
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-8 DURATION OF CKD SYMPTOMS
 
 
No. of patients Percentage
-6 18 
12 24 
-18 4 
-24 1 
-30 3 
 50 
-4 -DURATION OF CKD SYMPTOMS
– 12 months of duration. Mean duration 
36%
48%
8%
2%
6%
SYMPTOMS DURATION
0-6 MONTHS 7-12 MONTHS 13-18 MONTHS
19-24 MONTHS 25-30 MONTHS
 
 
36% 
48% 
8% 
2% 
6% 
 
 
 
 TABLE – 9 – DISTRIBUTION OF CREATININE CLEARANCE IN 
Creatinine 
clearance(ml/minute)
<15 
15-30 
>30 
Total 
CHART – 5 – DISTRIBUTION OF CREATININE CLEARANCE IN 
Of the 50 patients, 33 
accounting to 66%, 15 patients had GFR ranging from 15 
accounting for 30% and 2 patients had GFR ranging from more than 
ml/minute accounting for 4%. Among the patients studied most were in the 
range of creatinine clearance <15 ml/minute.
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CKD PATIENTS 
 
No. of patients 
33 
15 
2 
50 
CKD PATIENTS 
patients had GFR of less than 15 ml/minute 
 
<15, 33
15 - 30, 15
>30, 2
CREATININE CLEARANCE
Percentage 
66% 
30% 
4% 
 
 
– 30 ml/minute 
– 30 
 TABLE – 10 – DISTRIBUTION OF BLOOD UREA IN CKD PATIENTS
Blood urea(in mg/dl)
40-80
81-120
121-160
161-200
CHART – 6 – DISTRIBUTION OF BLOOD UREA IN CKD PATIENTS
The blood urea
102.12. Among the patients studied most of them have blood urea in the range 
of 81- 120 mg/dl. 
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 No of patients
 14 
 24 
 8 
 4 
 value varied from 45 – 184 mg/dl, the mean value being 
28%
48%
16%
8%
BLOOD UREA
40-80 81-120 121-160 161-200
 
 
 
 
 TABLE – 11- DISTRIBUTION OF SERUM CREATININE IN CKD 
Serum creatinine(in mg/dl)
0-4.
4-8.
8-12.
12-16.
CHART – 7- DISTRIBUTION OF SERUM CREATININE IN CKD 
The creatinine values varied from 3 
7.34.  Among the patients study most of them have serum creatinine in the 
range of 4 – 8 mg/dl.
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PATIENTS 
 No of patients
 6 
 27 
 12 
 5 
PATIENTS 
– 14 mg/dl, the mean value being 
 
12%
54%
24%
10%
SERUM CREATININE
0-4. 4-8. 8-12. 12-16.
 
 
 TABLE – 12- DISTRIBUTION OF SERUM CALCIUM IN CKD 
Serum calcium(mg/dl)
Low 
Normal 
High 
Total 
CHART – 8- DISTRIBUTION OF SERUM CALCIUM IN CKD 
Serum calcium values were 
for 20%, normal in 28 patients accounting for 56% and high in 12 patients 
accounting for 24%. 
0
5
10
15
20
25
30
LOW
58 
PATIENTS 
 No. of patients Percentage
10 
28 
12 
50 
PATIENTS 
found to be low in 10 patients accounting 
NORMAL
HIGH
SERUM CALCIUM
 
20% 
56% 
24% 
100% 
 
 TABLE – 13- DISTRIBUTION OF SERUM PHOSPHORUS IN CKD 
Serum phosphorus 
(mg/dl) 
Low 
Normal 
High 
Total 
CHART – 9- DISTRIBUTION OF SERUM PHOSPHORUS IN CKD 
Serum phosphorus values were found to be high in 12 patients 
accounting for 24% and the remaining 38 patients were found to be in normal 
range accounting for 76%.
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PATIENTS 
No. of patients Percentage
0 
38 
12 
50 
 
PATIENTS 
 
LOW
NORMAL
HIGH
SERUM PHOSPHORUS
SERUM PHOSPHORUS
 
0% 
76% 
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 TABLE – 14- DISTRIBUTION OF LOW T3 AMONG VARIOUS 
TSH level 
Normal 
High 
Total 
X2- 2.24 
p>0.05 (Not significant)
CHART – 10- DISTRIBUTION OF LOW T3 AMONG VARIOUS 
 In our study out of 50 patients, 33 patients had low serum T3 levels 
(66%). 4 patients among low serum T3 value, they also had low T4 and high 
TSH suggesting primary hypothyroidism (8%). So excluding 4 patients of 
hypothyroidism 29 patients had low T3 syndrome in our study.
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LEVELS OF TSH 
LOW T3 NORMAL T3
29 
4 
33 
 
LEVELS OF TSH                              
29
17
Low T3 Normal T3
 
17 
0 
17 
 
 
 TABLE – 15 - DISTRIBUTION OF LOW T4 AMONG VARIOUS 
TSH level 
Normal 
High 
Total 
X2-9.23 
p<0.05 (significant) 
CHART – 11 - DISTRIBUTION OF LOW T4 AMONG 
 16 patients had low T4 levels in our study, out of which 4 patients had 
low T3 and high TSH suggesting primary hypothyroidism. Excluding 
hypothyroidism 12 (24%) patients had low T4 in our study.
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LEVELS OF TSH 
LOW T4 NORMAL T4
12 
4 
16 
 
LEVELS OF TSH
 
12
34
LOW T4 NORMAL T4
 
34 
0 
34 
VARIOUS 
 
  TABLE
Thyroid 
dysfunction 
Normal value
T3 
T4 
TSH 
X2-12.71 
p<0.05(significant) 
CHART-12: ANALYSIS OF T3, T4, TSH EXCLUDING 
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-16: ANALYSIS OF T3, T4, TSH EXCLUDING 
HYPOTHYROIDISM 
No. of patients with 
 Low value 
17 29 
34 12 
46 Nil 
HYPOTHYROIDISM. 
Normal 
low
high
17 29
0
34
12
46
0
T3 T4 TSH
High value 
Nil 
Nil 
Nil 
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The TSH values in our study ranged from 0.6-38 micro IU/ml, the mean value 
being 6.494. Among 50 patients, 46 patients were in the normal range and 4 
patients had high value of more than 20 micro IU/ ml. In patients who were in 
the high range 3 were males and 1 was female. 
 The all four patients with primary hypothyroidism had creatinine 
clearance of less than 15 ml/min. It indicates the severity of renal failure in 
hypothyroid patients. 
 In our study of CKD patients with low T3 syndrome, the mean TSH 
values in several stages of renal failure are found to be in normal range. TSH 
values did not show any linear correlation with glomerular filtration rate in our 
study. 
 
 
 
 
 
 
  
 TABLE – 17 - ANALYSIS OF HYPOTHYROID SYMPTOMS IN CKD
X2-2.04 
p>0.05(Not significant)
CHART – 13 - ANALYSIS OF HYPOTHYROID SYMPTOMS IN CKD
 Out of 50 patients in our study 34 patients (68%) had the symptoms 
suggestive of hypothyroidism such as tiredness, weakness, cold intolerance, dry 
coarse skin, constipation, hoarseness of voice, loss of hair, etc., 
Variants 
Low T3 
Primary hypothyroidism
CKD without thyroid dysfunction
Total 
Low T3
Primary hypothyroidism
CKD without thyroid 
dysfunction
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Total No. of 
patients 
No. of patients 
with symptoms
29 19 
 4 4 
 17 11 
50 34 
0 10 20 30 40 50
Total
Percentage
No. of patients with 
symptoms
Total No. of patients
 
 
 
 
 
 
 
 
 
 
Percentage 
65.51% 
100% 
64.7% 
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 Out of 29 patients who had low T3 syndrome, 19 patients had symptoms 
suggestive of hypothyroidism accounting for 65.5% and 4 patients among the 
primary hypothyroidism, all four had symptoms of hypothyroidism which 
accounts for 100%. 
 Among 50 patients of CKD, 17 patients did not show any thyroid 
function abnormalities but out of them 11 had symptoms suggestive of 
hypothyroidism which accounts for 64.7%. 
 Features of hypothyroidism such as delayed ankle jerk was present in 2 
patients, out of which one were hypothyroid. Papilloedema was found in one 
patient who is a hypothyroid and goitre was found in one patient who is a 
hypothyroid. 24 hours urinary protein excretion was < 1g/day in all the patients 
in our study. 
 Out of 50 patients in our study, 42 patients had anaemia, out of which 34 
patients revealing normocytic normochromic anaemia in peripheral smear 
study and the remaining 8 patients had microcytic hypochromic anaemia. 
 In our study, ultrasound abdomen was done in all patients, that showed 
features of contracted kidney in 46 patients accounting for 92% and the 
remaining 4 patients had loss of cortico-medullary differentiation.  
 
  
 TABLE – 18 - ANALYSIS OF THYROID DYSFUNCTION IN THIS 
Thyroid dysfunction
Low T3 syndrome
Low T4 syndrome
Hypothyroidism 
CHART – 14 - ANALYSIS OF THYROID DYSFUNCTION IN THIS 
 
Among the patients study 58% had low T3 syndrome, 24% had low T4 
syndrome and 8% had primary 
Low T4 
syndrome, 12
66 
STUDY 
 No. of patients Percentage
 29 58%
 12 24%
4 
STUDY 
hypothyroidism 
Low T3 
syndrome, 29
Hypothyroidism, 
4
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TABLE-19: DISTRIBUTION OF CREATININE CLEARANCE IN 
PATIENTS WITH LOW T3 SYNDROME.
Creatinine clearance 
(ml/minute) 
Less than 15 
15 – 30 
More than 30 
X2-0.279 
p>0.05(Not significant)
CHART-15: DISTRIBUTION OF CREATININE CLEARANCE IN 
PATIENTS WITH LOW T3 SYNDROME.
 
 
Creatinine clearance were found to be less than 15 ml/minute in 20 
patients of low T3 syndrome, 15 
ml/minute in 1 patient.
67 
15 – 30 More than 30
Total no. of patients
Patients with low T3 
syndrome
Total no. of 
patients 
Patients with low 
T3 syndrome 
33 20 
15 8 
2 1 
 
– 30 ml/minute in 8 patients 
 
 
Percentage 
60.60% 
53.33% 
50% 
 
and more than 30 
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TABLE-20: DISTRIBUTION OF CREATININE CLEARANCE IN 
PATIENTS WITH LOW T4 SYNDROME. 
Creatinine 
clearance 
(ml/minute) 
Total no. of 
patients 
Patients with low  
T4 syndrome 
Percentage 
Less than 15 33 13 39.39% 
15 – 30 15 3 20% 
More than 30 2 0 0% 
X2-2.763 
p>0.05(Not significant) 
CHART-16: DISTRIBUTION OF CREATININE CLEARANCE IN 
PATIENTS WITH LOW T4 SYNDROME. 
 
 
 
 
 
 Creatinine clearance were found to be less than 15 ml/minute in 13 
patients of low T4 syndrome, 15 – 30 ml/minute in 3 patients and no patients 
were in the range of more than 30 ml/minute. 
0
5
10
15
20
25
30
35
Less than 15 15 – 30 More than 30
Total no. of patients
Patients with low  T4 
syndrome
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TABLE – 21 - AGE INCIDENCE OF LOW T3 SYNDROME IN THIS 
STUDY 
Age in years 
Total no. of 
patients 
Patients with 
low T3 
syndrome 
Percentage 
<30 9 4 44.44% 
30 – 60 35 21 60% 
>60 6 4 66.66% 
X2-0.921 
p>0.05(Not significant) 
CHART  – 17 - AGE INCIDENCE OF LOW T3 SYNDROME IN THIS 
STUDY 
 
Age incidence of CKD patients with low T3 syndrome in our study 
showed that, CKD patients having low T3 syndrome 44.44% were less than 30 
years of age, 60% were in the age group 30 – 60 years of age and 66.66% were 
more than 60 years of age. It tells that as the age increases number of patients 
with low T3 syndrome also increases. 
0
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35
40
<30 30 – 60 >60
Total no. of patients
Patients with low T3 
syndrome
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TABLE-22: SEX INCIDENCE OF LOW T3 SYNDROME IN THIS 
STUDY. 
Sex 
Total no. of 
patients 
Patients with 
low T3 
syndrome 
Percentage 
Males 34 20 58.82% 
Females 16 09 56.25% 
Total 50 29 
 
X2-0.558 
p>0.05(Not significant) 
CHART-18: SEX INCIDENCE OF LOW T3 SYNDROME IN THIS 
STUDY. 
 
Sex incidence of CKD patients with low T3 syndrome in our study 
showed that 58.82% of males and 56.25% females had low T3 syndrome. 
0
10
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50
60
Males Females Total
Total no. of patients
Patients with low T3 
syndrome
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TABLE – 23– CORRELATION OF THYROID HORMONES 
EXCLUDING HYPOTHYROIDISM 
Thyroid 
hormones 
Normal 
range 
Study 
range 
Mean SD 
Mean 
excluding 
hypothyroidism 
SD 
Serum T3 0.6-2.1 0.2-2.0 0.67 0.53 0.706 0.53 
Serum T4 5-13 0.9-8.5 5.65 2.31 5.94 2.31 
Serum TSH 0.4-7 0.6-38 6.49 6.99 4.55 6.99 
In our study T3 level ranges from 0.2 – 2.0 ng/ml, the mean value being 
0.67. T4 level ranges from 0.9 – 8.5 micro g/dl, the mean value being 5.65. 
TSH level ranges from 0.6 – 38 micro IU/ml, the mean value being 6.49. 
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TABLE – 24 - CORRELATION OF THYROID HORMONES WITH 
SEVERITY OF RENAL FAILURE EXCLUDING HYPOTHYROIDISM 
Creatinine 
clearance 
(ml/minute) 
 
T3 
 
T4 
 
TSH 
 Mean SD Mean SD Mean SD 
<15 0.67 0.52 5.78 2.30 4.47 5.50 
15 – 30 0.72 0.47 6.04 2.28 4.60 7.97 
>30s 1.05 0.73 7.55 2.63 5.35 8.10 
 
  
 TABLE – 25 – 
Primary hypothyroidism
No 
Yes 
X2 = 35.57 
p < 0.05 significant  
CHART – 19 –
Among 50 patients included in our study 33 had low T3 level, among 
which 4 patients low T3 was due to primary hypothyroidism and the rest 29 
patients had low T3 mainly due to influence of CKD which was also significant 
statistically(P<0.05).
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DISCUSSION 
The present  study  was  aimed  at  to assess  the  prevalence of  thyroid  
dysfunction in CKD  patients and to determine the correlation between thyroid 
dysfunction and severity of renal disease. Various  studies  was conducted  
about thyroid dysfunction and  severity  of  CKD  and  shown  different  
results. 
In our study, CKD patients only on conservative management were 
studied. This is because thyroid profile undergoes changes due to dialysis 
independent of that due to chronic kidney disease. Dialysis also changes the 
previous serum thyroid hormone status in patients with renal failure. Various 
studies have been studied by comparing CKD patients on conservative 
Management and patients on HD by Ramirez79 and Kayima et al80. 
 In our study 50 patients of CKD who were on conservative management 
fulfilling the criteria for CKD were studied, among these 50 patients, 34 were 
males and 16 were females, their age varied from 20 - 68 years. Among these 
50 patients, patients who were 30 years old and below were 9, between 31 - 60 
years were 35 and 60 years of age and above were 6 in number. 
Among the 50 patients study, 68% of patients were males and 32% 
patients were females. 
In our study the duration of symptoms of CKD varied from 4 months to 
30 months, mean duration being 9.84 months and the creatinine clearance 
varied from 6 ml/minute- 32 ml/minute. 
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Of the 50 patients, 33 patients had GFR of less than 15 ml/minute 
accounting to 66%, 15 patients had GFR ranging from 15 – 30 ml/minute 
accounting for 30% and 2 patients had GFR ranging from more than – 30 
ml/minute accounting for 4%. 
Among the patients studied most were in the range of creatinine 
clearance <15 ml/minute. 
The blood urea value varied from 45 – 184 mg/dl, the mean value being 
102.12. Among the patients studied most of them have blood urea in the range 
of 81-120 mg/dl 
The creatinine values varied from 3 – 14 mg/dl, the mean value being 
7.34. Among the patients study most of them have serum creatinine in the 
range of 4 – 8 mg/dl 
Serum calcium values were found to be low in 10 patients accounting 
for 20%, normal in 28 patients accounting for 56% and high in 12 patients 
accounting for 24%. 
Serum phosphorus values were found to be high in 12 patients 
accounting for 24% and the remaining 38 patients were found to be in normal 
range accounting for 76%. 
24 hours urinary protein excretion was < 1g/day in all the patients in our 
study. 
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Out of 50 patients in our study, 42 patients had anaemia, out of which 34 
patients revealing normocytic normochromic anaemia in peripheral smear 
study and the remaining 8 patients had microcytic hypochromic anaemia. 
 In our study, ultrasound abdomen was done in all patients, that showed 
features of contracted kidney in 46 patients accounting for 92% and the 
remaining 4 patients had loss of cortico-medullary differentiation which 
accounts for 8%. 
In our study out of 50 patients, 33 patients had low serum T3 levels 
(66%). 4 patients among low serum T3 value, they also had low T4 and high 
TSH suggesting primary hypothyroidism (8%). So excluding 4 patients of 
hypothyroidism 29 patients had low T3 syndrome in our study. 
16 patients had low T4 levels in our study, out of which 4 patients had 
low T3 and high TSH suggesting primary hypothyroidism. Excluding 
hypothyroidism 12 (24%) patients had low T4 in our study. 
The TSH values in our study ranged from 0.6-38 micro IU/ml, the mean 
value being 6.494. Among 50 patients, 46 patients were in the normal range 
and 4 patients had high value of more than 20 micro IU/ ml. In patients who 
were in the high range 3 were males and 1 was female. 
 The all four patients with primary hypothyroidism had creatinine 
clearance of less than 15 ml/min. It indicates the severity of renal failure in 
hypothyroid patients. 
77 
 
 Excluding hypothyroidism, mean TSH level in our study is within 
normal limits. The mean TSH levels are also within normal limits for the 
various ranges of GFR. But TSH level doesn’t show any linear correlation with 
the severity of renal failure. 
 In our study of CKD patients with low T3 syndrome, the mean TSH 
values in several stages of renal failure are found to be in normal range. TSH 
values did not show any linear correlation with glomerular filtration rate in our 
study. 
 One similar  study  showed similar  results  which was  conducted by 
Spector and Ramirez et al 79,81Dudani et al82, Karunanidhi et al83. These studies 
depicted   abnormality in hypophyseal mechanism of TSH release in uraemic 
patients as the TSH response to the TRH was blunted. 
 Another  study  which was  conducted by Joseph et al and Hardy et 
al84,85revealed low T3 T4 level with high TSH level suggesting maintenance of 
pituitary thyroid axis. 
 Several studies reported in CKD patients showed low T3 values. Low 
T3 had been reported in Ramirez et al79, Hegedus et a137, Beckett et al86PonAjil 
Singh et al27, P Iglesias and JJ Diez7 and many others. Ramirez and Spector et 
a179,81 study showed linear correlation between mean serum T3 and T4 and 
severity of renal failure. 
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 Among 50 patients of CKD, 17 patients did not show any thyroid 
function abnormalities but out of them 11 had symptoms suggestive of 
hypothyroidism which accounts for 64.7%. 
 Features of hypothyroidism such as delayed ankle jerk was present in 2 
patients, out of which one were hypothyroid. Papilloedema was found in one 
patient who is a hypothyroid and goitre was found in one patient who is a 
hypothyroid. 
 Previous studies by Quionverdeet a188 reported high preponderance of 
hypothyroidism in CKD. It was estimated to be about 5% in patients with 
terminal stage of renal failure. 
 Elaborated study by Kaptein et al5,89 estimated the prevalence of primary 
hypothyroidism was about 2.5 times much frequent in chronic kidney disease 
and dialysis. The hypothyroidism in CKD was estimated to range between 0 
and 9.5% 
 Kaptein study also estimated the presence of anti thyroid antibody titer 
in 6.7% of CKD. 
 In our study, hypothyroidism is present in 8% of the patients but doesn’t 
correlate with the severity of the renal failure. The symptoms of 
hypothyroidism were distributed equally in both hypothyroid and CKD patients 
in our study. 
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 So, diagnosis of hypothyroidism in CKD mainly rest on TSH level 
which should be very high (>20 µIU/dl) with low serum T4. In this study none 
of the patients had clinical or biochemical features of hyperthyroidism. 
 Age incidence of CKD patients with low T3 syndrome in our study 
showed that, CKD patients having low T3 syndrome 44.44% were less than 30 
years of age, 60% were in the age group 30 – 60 years of age and 66.66% were 
more than 60 years of age. It tells that as the age increases number of patients 
with low T3 syndrome also increases. 
 Among the patients study 58% had low T3 syndrome, 24% had low T4 
syndrome and 8% had primary hypothyroidism. 
Creatinine clearance were found to be less than 15 ml/minute in 20 
patients of low T3 syndrome, 15 – 30 ml/minute in 8 patients and more than 30 
ml/minute in 1 patient. 
Creatinine clearance were found to be less than 15 ml/minute in 13 
patients of low T4 syndrome, 15 – 30 ml/minute in 3 patients and no patients 
were in the range of more than 30 ml/minute. 
As with other studies, mean T3 level in our study was reduced in GFR 
less than 15 ml/min. In patients with low GFR, T3 level was found to be 
reduced and it shows there was direct linear relationship between T3 level and 
GFR, which is consistent with Avinashi et al study. 
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GOITRE: 
 Ramirez et a17 9showed high preponderance of goiter in patients with 
CKD especially those on chronic dialysis. The incidence was found to be 
increased in end stage renal disease. The possible explanation is due to 
accumulation of iodides in Thyroid gland due to decreased renal clearance in 
CKD patients. Apart from goiter, study reported by Hegedus et al37 showed 
thyroid gland volume was significantly increased in patients with CKD. In our 
study, one hypothyroid patient had goitre. 
DIALYSIS: 
As stated previously, HD and continuous ambulatory peritoneal dialysis 
have shown to affect the thyroid profile independently of CKD. Also drugs like 
heparin, furosemide used during dialysis will affect the thyroid profile. 
Kayimaet a180 and Giordano et al   have showed 90 studies regarding 
effect of dialysis on CKD patients with thyroid dysfunction.  
These studies showed no significant improvement in thyroid profile 
after repeated hemodialysis. But in the patients who have undergone renal 
transplant surgery, most of the thyroid   function parameters returned to normal 
with TSH below normal87. 
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CONCLUSION 
 In my study population, 50 CKD patients who were on conservative 
management were studied. Among them 66% of the patients had low T3 
values. 
 The change in the serum levels of T3 and T4 in patients with CKD can 
be considered as being protective, promoting conservation of protein.  
 There is progressive increase in the number of patients with Low T3 and 
T4 syndrome with the severity of renal failure. 
 There is increase in incidence of hypothyroidism in patients with 
chronic kidney disease.  
 Excluding hypothyroidism T3 level is found to be low in 58% of the 
patients and T4 level is low in 24% of the patients. . 
 As the age increases there is increase in incidence of Low T3 
syndrome in patients with CKD. 
 In patients with low GFR the serum T3 level was found to be 
decreased. This shows a direct linear relationship between GFR and T3 
level. 
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SUMMARY 
In our study 50 patients of CKD who were on conservative management 
admitted in Department of  Medicine, Coimbatore medical college & hospital, 
Coimbatore were studied for thyroid function abnormalities. 
 Age ranges from 20-68 years. 
 Male patients were 34 accounting 68% and female patients were 16 
accounting 32% 
 Duration of CKD symptoms ranges from 4 months to 30months, the 
mean being 9.84 months. 
 Creatinine clearance ranges from 6ml/min – 32ml/min. 
 Blood urea values varied from 45-184mg/dl, the mean being 102.12 
 Serum  creatinine levels varied from 3 – 14mg/dl, the mean being 7.34 
 Serum calcium level found to be low in 10 patients, normal in 28 
patients and high in 12 patients. 
 Serum phosphorous level found to be low in 12 patients and remaining 
38 patients are in normal range. 
 The study range of serum T3 was 0.2 – 2.0ng/ml, the mean being 0.67 
(normal range 0.6 – 2.1ng/ml), serum T4 was 0.9 – 8.5µg/dl, the mean 
being 5.65 (normal range 5-135µg/dl) and serum TSH was 0.6 – 
38µIU/ml, the mean being 6.49 (normal range 0.4-7 µIU/ml).  
 In our study 29 patients had low T3 syndrome, 12 patients had low T4 
syndrome and 4 patients had hypothyroidism.  
 The symptoms of hypothyroidism were seen in 34 patients constituting 
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68%. 
 As age increases the incidence of Low T3 syndrome also increases in 
our study. 
 According to our study number of patients with low T3 increases with 
increase in the severity of chronic kidney disease.  
 Number of patients with low T4 syndrome does not correlate with the 
severity of renal failure. 
 In low GFR patients the serum T3 level was found to be decreased. 
 In patients with low T3 syndrome, the mean values of TSH in various 
stages of renal disease are within normal range, and values of TSH did 
not show any correlation with GFR. 
 The low T3 state of CKD can be considered as being protective, 
promoting conservation of protein.  
LIMITATIONS OF THIS STUDY 
Thyroid dysfunction was studied in patients with CKD irrespective of 
the etiology of CKD therefore individual correlation of the etiology of CKD 
with thyroid dysfunction could not be studied. 
Thyroid dysfunction was not studied in patients on dialysis, as dialysis 
itself affects the thyroid profile independently of CKD.  
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Proforma 
 
PROFORMA 
 
NAME:                                                               AGE:                    SEX:                        IP NO: 
OCCUPATION: 
ADDRESS: 
PAST HISTOY:   HYPERTENSION- Y/N 
DIABETES- Y/N 
RECENT SURGERY/TRAUMA-Y/N 
DRUGS- Y/N 
 JAUNDICE-Y/N 
OTHER SYSTEMIC ILLNESS-Y/N 
MENSTRUAL & OBSTRETIC HISTORY: 
GENERAL EXAMINATION: 
         1. NOURISHMENT 
         2. PALLOR 
         3. HYPERPIGMENTATION 
         4. FACIAL PUFFINESS 
         5. PEDAL EDEMA 
         6. SKIN TEXTURE 
         7. THYROID SWELLING 
PULSE:                                BP: 
RR: 
TEMPERATURE: 
CVS: 
RS: 
ABDOMEN: 
CNS: 
INVESTIGATIONS: 
1. URINE ROUTINE 
2. BLOOD:   HB-      g/dl 
i. TC- 
ii. DC- P   %,L    %,E    % 
iii. RBC-              cells/cu.mm 
iv. BT- 
v. CT- 
3. BLOOD SUGAR: 
4. BLOOD UREA: 
5. SERUM CREATININE: 
6. SERUM ELECTROLYTES: 
i. SODIUM- 
ii. POTASSIUM- 
iii. CALCIUM- 
iv. PHOSPHOROUS- 
v. URIC ACID- 
7. SERUM CHOLESTEROL: 
a. SERUM PROTEIN:         a. TOTAL- 
                                                      b. ALBUMIN- 
c. GLOBULIN- 
8. ECG: 
9. CHEST XRAY: 
10. 24 HOUR URINARY PROTEIN: 
11. USG ABDOMEN: 
12. THYROID PROFILE:      a. TOTAL T3  -   
b. TOTAL T4 
c. TSH- 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Master Chart 
MASTER CHART 
S.NO NAME IP NO AGE SEX SYMPTOM 
DURATION
UREA 
mg/dl
CREATININ
E mg/dl
CCL 
ml/min
CALCIUM 
mg/dl
PHOSPHOUS  
mg/dl
T3                 
ng/ml
T4
mg/dl
TSH 
mIU/ml
USG ABD MISCELLANEOUS
1 sivaraj 40043 28 M 12 112 12.2 6 9.3 4 0.2 1.2 4.5 blck 1
2 arumugam 40208 62 M 8 89 10.6 7 8 4.2 0.3 3.2 29 cmdl 1,3
3 karupusamy 39271 53 M 7 102 8.7 6 7.6 4.6 1.2 6.3 3.7 blck 1
4 vivekanda 39975 44 M 9 164 7.6 9 10.2 3.8 0.4 0.9 5.3 blck 2
5 gomathy 41869 47 F 24 119 9.2 8 9.6 2.9 0.3 7.4 3.5 blck nil
6 jothiraj 41714 49 M 6 86 4.5 7 8.9 3.9 0.8 7.2 2.8 blck 1
7 krishnan 43527 60 M 8 78 5.6 6 7.7 5.2 0.3 8.5 0.6 blck nil
8 subramani 43565 59 M 10 167 11.2 8 8.1 4.1 0.3 8.3 6.5 cmdl nil
9 poovathal 46071 65 F 6 99 6.7 8 9.7 3 0.4 3.2 0.9 blck 1
10 manokaran 47072 55 M 4 104 13.2 6 11 3.5 0.5 2.3 26 blck 1,2
11 manikandan 47011 38 M 30 136 14 7 8.7 4.8 0.4 4.2 5.7 blck 1
12 muthusamy 47196 24 M 10 104 11.2 9 11.4 3.6 0.8 6.1 3.6 blck 1
13 rajendran 47093 56 M 5 78 6.7 7 8.5 3.8 0.3 6.7 6.4 blck nil
14 chandra 47545 63 F 8 89 4.5 6 8.8 3.4 1.1 6.7 3.6 blck 1
15 selvamani 43565 57 M 7 54 5.6 9 9.6 2.9 0.4 3.5 5.6 blck 1
16 ramasamy 46001 25 M 11 78 3.6 6 8.2 3.1 1.9 7.8 5.3 blck 1
17 palani 47072 30 M 18 184 8.6 8 9.5 4.1 0.2 6.3 4.8 blck 1
18 chandrasekar 56248 24 M 6 136 9.2 9 7.8 4.4 1.5 6.5 5.6 blck 1
19 chandrakala 56784 42 F 12 146 10.2 6 11 3.6 0.5 4.6 3.2 blck 1
20 sasikumar 56203 39 M 4 66 3 8 10.6 3.4 1.9 8 4.6 blck nil
21 ponnuthai 57203 64 F 10 109 7.2 7 9.8 3.9 0.2 1.6 2.8 blck 1
22 veera 57654 56 M 6 127 7.6 9 8.9 3.2 0.2 2.2 4.3 blck nil
 23 haridass 66890 31 M 9 136 5.6 9 7.9 5.2 1.6 8.2 5.6 blck 2
24 gunasekaran 56789 61 M 5 123 4.7 7 9 4.3 0.5 7.4 6.3 blck 2
25 venkateshwaran 69010 43 M 30 167 7.2 8 10.2 3.6 0.4 3.9 3.8 blck 1
26 mariammal 68798 39 F 8 107 3.6 9 8.9 3.9 0.3 7.2 6.5 blck 1
27 manjunath 69010 26 M 12 62 7.6 8 11.5 3.6 2 7.8 4.8 blck 1
28 muthusamy 77131 68 M 4 76 3.2 7 8.7 4.5 0.3 6.6 5.6 blck nil
29 janaki 77521 48 F 8 88 4.6 30 9.1 4.2 1 8.1 3.5 blck 1
30 jesudas 80304 47 M 6 85 6.7 13 9.9 3.8 0.2 5.9 6.3 blck 1
31 manikandan 81532 54 M 7 97 5.3 16 8.4 3.9 0.2 6.3 6.2 blck 1
32 chandrasekar 81564 21 M 30 92 9.7 15 9.9 4.1 0.4 0.9 3.5 blck 1
33 poornima 82350 47 F 8 56 6.7 18 9.3 3.8 0.4 6.1 3.8 blck 1
34 selvakumar 82553 26 M 6 78 4.6 26 10.6 3.6 0.9 5.8 2.3 blck 1
35 jayalakshmi 88765 57 F 5 112 11.2 12 9.5 2.9 0.5 6.7 3.9 blck nil
36 vellingiri 88906 46 M 8 109 12.5 18 8.8 4.7 0.3 8.2 4.6 blck 1
37 suguna 87695 39 F 10 135 13.6 17 10.9 3.8 0.5 7.5 6.5 blck nil
38 karupathal 77896 54 F 6 122 3.7 28 10.1 3.4 0.8 7.4 4.3 blck nil
39 elango 77619 60 M 4 105 5.9 32 9.3 2.9 1.8 7.4 4.9 blck 1
40 ramalingam 77654 39 M 12 116 9.5 24 11.1 3.3 0.4 8.1 6.7 cmdl nil
41 palanisamy 77890 48 M 16 119 6.7 7 9.7 3.7 0.3 2.5 22 blck 1
42 kokila 77687 20 F 18 117 5.6 32 10.9 3.8 0.3 7.7 5.8 blck nil
43 muruganandhan 77854 23 M 14 89 4.5 18 11 3.1 0.5 2.6 3.6 blck 1
44 suryaprakash 78654 54 M 6 78 5.6 30 7.8 5.5 0.3 6.3 6.5 blck nil
45 arukani 78950 47 F 8 65 3.7 22 9.5 3.4 1.4 3.6 5.2 blck nil
46 gunasekaran 76843 38 M 6 82 5.7 12 9.9 3.5 0.5 6.8 3.8 blck 1
47 vijaya 76549 48 F 7 89 7.6 13 10.7 2.6 0.3 1.1 38 cmdl 1,4
48 marimuthu 78659 35 M 5 65 7 28 10.8 2.8 1.7 6.6 6.2 blck nil
49 sivagami 77652 32 F 7 45 8.2 22 9.9 3.8 0.8 6.3 1.2 blck nil
50 chinnammal. 66789 56 F 6 64 5.6 26 8.2 4.8 1.2 6.8 5 blck 2
KEY TO MASTER CHART 
 
1 - Hypothyroid symptoms present 
2 - Delayed ankle jerk 
3 - Papilledema 
4 - Goitre 
CCL - Creatinine Clearance  
T3 - Triiodothyronine 
T4 - Thyroxine 
TSH - Thyroid Stimulating Homrone 
BLCK - Bilateral contract kidney 
CMDL - Cortico – medullary differentiation lost 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
Consent Form 
 
CONSENT FORM 
You, Shri./ Smt./ Kum. _________________________, aged ____ years, S/o / 
D/o / W/o ___________________________, residing at ________________ 
_______________________________________ are requested to be a participant in 
the research study titled “A STUDY OF THYROID FUNCTION 
ABNORMALITIES IN PATIENTS WITH CHRONIC KIDNEY DISEASE”. in 
Government Medical College Hospital, Coimbatore, conducted by DR RAJESH S., 
Post Graduate Student in the Department of General Medicine, Coimbatore Medical 
College. You satisfy eligibility criteria as per the inclusion criteria. You can ask any 
question or seek any clarifications on the study that you may have before agreeing to 
participate. 
Research Being Done 
“A STUDY OF THYROID FUNCTION ABNORMALITIES IN PATIENTS 
WITH CHRONIC KIDNEY DISEASE”. 
Purpose of Research 
 To study thyroid function abnormalities in patients with chronic kidney 
disease. 
 To correlate the thyroid function abnormalities with severity of renal failure. 
 To differentiate primary hypothyroidism from thyroid dysfunction due to 
chronic kidney disease. 
Procedures Involved 
The research includes detailed clinical examination including medical history, 
physical examination.  
 
 
Decline from Participation 
You are hereby made aware that participation in this study is purely voluntary and 
honorary and that you have the option and the right to decline from participation in the 
study. 
Privacy and Confidentiality 
You are hereby assured about your privacy.  Privacy of subject will be respected and 
any information about you or provided by you during the study will be kept strictly 
confidential. 
Authorization to Publish Results   
Results of the study may be published for scientific purposes and/or presented to 
scientific groups, however you will not be identified; neither will your privacy be 
breached. 
Statement of Consent 
I, _____________________, do hereby volunteer and consent to participate in this 
study being conducted by DR RAJESH S. I have read and understood the consent 
form / or it has been read and explained to me. The study has been fully explained to 
me, and I may ask questions at any time. 
 
Signature / Left Thumb Impression of the Volunteer  Date: 
 
Signature and Name of witness     Date: 
xg;g[jy; gotk; 
 
bgah;   : 
 
taJ   : 
 
ghypdk;  : 
 
Kfthp  : 
 
 muR nfhit kUj;Jtf; fy;Y}hpapy; bghJ kUj;jt Jiwapy; gl;;l nkw;gog;g[ 
gapYk; khzth] kU.nr.uhn$#; mth;fs; nkw;bfhs;Sk; “ePz;l ehs; rpWePuf 
ghjpg;g[s;s nehahspfspy; ijuha;L mrhjhuz bray;ghLfs; Fwpj;J xU Ma;t[” 
gw;wpa bra;Kiw kw;Wk; midj;J tpsf;f';fisa[k; nfl;Lf; bfhz;L vdJ 
re;njf';fis bjspt[g;gLj;jpf; bfhz;nld; vd;gij bjhptpj;Jf; bfhs;fpnwd;. 
 ehd; ,e;j Ma;tpy; KG rk;kjj;JlDk;/ Ra rpe;jida[lDk; fye;J bfhs;s 
rk;kjpf;fpnwd;. 
,e;j Ma;tpy; vd;idg; gw;wpa midj;J tptu';fs; ghJfhf;fg;gLtJld; 
,jd; Kot[fs; Ma;tpjHpy; btspaplg;gLtjpy; Ml;nrgid ,y;iy vd;gij 
bjhptpj;Jf; bfhs;fpnwd;. ve;j neuj;jpYk; ,e;j Ma;tpy; ,Ue;J ehd; tpyfpf; 
bfhs;s vdf;F chpik cz;L vd;gija[k; mwpntd;. 
 
,lk; : 
njjp :        ifbahg;gk; / nuif 
  
